1. The effect of posterior vitreous detachment on aflibercept response in diabetic macular oedema.
- Author
-
Özsaygili C, Küçük B, and Yildirim Y
- Subjects
- Aged, Angiogenesis Inhibitors administration & dosage, Diabetic Retinopathy complications, Diabetic Retinopathy diagnosis, Female, Follow-Up Studies, Humans, Intravitreal Injections, Macular Edema diagnosis, Male, Middle Aged, Retrospective Studies, Tomography, Optical Coherence methods, Treatment Outcome, Vascular Endothelial Growth Factor A antagonists & inhibitors, Vitreous Detachment diagnosis, Vitreous Detachment etiology, Diabetic Retinopathy drug therapy, Macular Edema drug therapy, Receptors, Vascular Endothelial Growth Factor administration & dosage, Recombinant Fusion Proteins administration & dosage, Vitreous Detachment drug therapy
- Abstract
Purpose: To investigate the effect of posterior vitreous detachment (PVD) on aflibercept response in treatment-naïve diabetic macular oedema (DME)., Design: A retrospective cohort study., Methods: One hundred and fifty eyes of 150 treatment-naïve patients with DME were enrolled. The patients were divided into three groups according to their PVD status: group 1 (no PVD during injections), group 2 (PVD during injections) and group 3 (PVD already present initially). Three consecutive aflibercept injections at intervals of 1 month were applied to all patients. The efficacy of the aflibercept treatment on DME was assessed by comparing changes in central retinal thickness (CRT) and best-corrected visual acuity (BCVA) values after three loading dose injections., Results: After three consecutive injections, the mean reduction of CRT in groups 1, 2 and 3 were -199.6±106.9, -224.9±124.1 and -210.7±126.3, respectively. The decrease in CRT was significant in all groups (p<0.001 in all groups, paired-samples t-test); however, mean changes in CRT were similar among groups (all p>0.05, one-way analysis of variance (ANOVA)). The mean improvement in BCVA in groups 1, 2 and 3 was 6.6±0.9, 6.5±0.8 and 6.1±0.4 ETDRS letters, respectively. The improvement of BCVA was significant in all groups (p<0.001 in all groups, paired-samples t-test) and mean changes were similar between groups (p>0.05, one-way ANOVA). There was no significant relationship between the presence or development of PVD and the mean decrease of CRT and improvement of BCVA (for CRT r=-0.052, p=0.531 and for BCVA r=-0.078, p=0.342)., Conclusion: In the present study, it was observed that the efficacy of aflibercept treatment in patients with DME did not depend on PVD status., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF